FY2024 EPS Estimates for BrainsWay Lifted by HC Wainwright

BrainsWay Ltd. (NASDAQ:BWAY) – HC Wainwright increased their FY2024 earnings per share (EPS) estimates for BrainsWay in a research report issued on Monday, December 23rd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.14 per share for the year, up from their previous forecast of $0.06. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.06 per share. HC Wainwright also issued estimates for BrainsWay’s Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at $0.06 EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.10 EPS and FY2025 earnings at $0.32 EPS.

Separately, Northland Securities boosted their target price on BrainsWay from $11.00 to $12.50 and gave the stock an “outperform” rating in a report on Thursday, October 3rd.

BrainsWay Stock Performance

BWAY stock opened at $9.37 on Wednesday. The company has a market capitalization of $176.28 million, a price-to-earnings ratio of 93.71 and a beta of 1.23. The business’s 50 day moving average price is $9.83 and its two-hundred day moving average price is $8.27. BrainsWay has a fifty-two week low of $4.61 and a fifty-two week high of $10.98.

BrainsWay (NASDAQ:BWAY) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The business had revenue of $10.50 million for the quarter, compared to analyst estimates of $10.07 million. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. During the same quarter last year, the firm earned ($0.01) EPS.

Institutional Investors Weigh In On BrainsWay

Institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC increased its holdings in BrainsWay by 48.1% in the 2nd quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock valued at $1,567,000 after acquiring an additional 84,371 shares during the last quarter. Good Life Advisors LLC boosted its holdings in shares of BrainsWay by 65.5% in the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock worth $516,000 after purchasing an additional 22,080 shares during the period. Perritt Capital Management Inc bought a new position in BrainsWay during the second quarter valued at $121,000. JPMorgan Chase & Co. grew its holdings in BrainsWay by 316.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock valued at $136,000 after purchasing an additional 11,221 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of BrainsWay by 10.3% in the second quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after buying an additional 1,695 shares during the period. Hedge funds and other institutional investors own 30.11% of the company’s stock.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.